Test drug NM8074 for PNH that isn’t responding enough to Soliris
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) and weigh at least 45 kg (about 99 lb).
- Your PNH diagnosis is confirmed by a specialized blood test (flow cytometry) showing a PNH clone size of 10% or more.
- You have ongoing hemolysis and recent anemia (hemoglobin 10.5 g/dL or less).
- You’ve had at least 1 red blood cell transfusion within the last 12 months, and your LDH blood test is elevated (1.5× the lab upper limit).
- You’re currently being treated with Soliris, and you can get meningitis vaccines (MenACWY and MenB) before starting the study drug.
- You can sign the consent form and follow the study visit schedule; you’re not pregnant (and you can follow required birth control rules if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
This trial is for people who have already completed the Phase 2 study of LP-005 and may continue receiving it. It checks how safe and effective the drug is over a longer period.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.